SEOUL-SEMICONDUCTOR
6.7.2020 11:02:12 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been adopted for horticulture LED lighting by the lighting solution company Fiberli , located in Turkey, one of the largest agricultural exporters in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005073/en/
While it is well known that natural sunlight is one of the key factors in growth cycle of a plant, most growers cultivating a variety of crops under sunlight have experienced difficulties in regulating their growth cycles due to adverse seasonal conditions. Replacing sunlight with LED lighting that closely matches natural sunlight enables growers to control the growth cycles and development of all types of crops all year-round in greenhouses and indoor farms.
Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the world’s first LEDs to produce light that closely matches the spectrum of natural sunlight. The SunLike Series LEDs adopted for horticulture LED lighting by Fiberli achieved a full spectrum of light wavelengths from 380nm to 740nm, similar to the spectral curve of natural sunlight, with a color temperature of 5000K optimized to daylight spectra and color properties of CRI97, CQS97, TM30=100. In co-operation with Fiberli, Seoul Semiconductor has delivered an optimal horticulture lighting solution that fulfills the requirements of the light source for effective cultivation of all varieties of crops and flowers.
Fiberli introduces their innovative horticulture lighting with SunLike with a demo installation of 1500 m2 .
“We are proud to launch the innovative horticulture LED lighting in co-operation with Seoul Semiconductor. Its SunLike Series natural spectrum LEDs are the first and only true sunlight LEDs that enable growers to ensure better yields and a consistently high quality of crops. We believe that market demand for horticultural LED lighting with SunLike LEDs will expand,” said Hakan Ozturk, director of Fiberli.
“The horticulture lighting market is growing fast, and our SunLike Series natural spectrum LEDs will offer the considerable benefits for customers to achieve optimal horticulture lighting solutions,” said Dr. Kim, CTO and vice president of Seoul Semiconductor. “We are pleased to expand this horticulture LED portfolio and will further diversify the customer base worldwide,” added Dr. Kim.
SunLike Series natural spectrum LEDs were co-developed through the combination of Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R technology, which defines its original concept as “the light closest to the sun for human well-being.” TRI-R technology enables the spectrum of natural sunlight to be reproduced by a white LED light source. TRI-R is a registered trademark of Toshiba Material Co., Ltd.
# # #
About Fiberli
Fiberli is a lighting solutions company located in Turkey. In cooperation with partners, it researches and develops lighting systems that reflect market demand and provide the best solutions for customers. Fiberli mainly delivers lighting for industrial and office spaces, greenhouses, indoor farms, parking and sports facilities. Based on a broad lighting portfolio, Fiberli offers differentiated service to customer from optimal guidance on the most suitable lighting solutions throughout the installation process. For more information, please visit https://fiberli.com.tr/EN
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 13,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom